Status:
COMPLETED
Candesartan in the Prevention of Relapsing Atrial Fibrillation
Lead Sponsor:
Asker & Baerum Hospital
Collaborating Sponsors:
Helse Ost
Ullevaal University Hospital
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist candesartan may reduce the recurrence rate of atrial fibrillation after electrical...
Detailed Description
Background: The most effective procedure to restore sinus rhythm in patients with persistent atrial fibrillation (AF) is electrical cardioversion, but AF recurs in 60-80% of the patients during the fi...
Eligibility Criteria
Inclusion
- Patients with atrial fibrillation, diagnosed electrocardiographically, of more than 48 hours duration in whom direct current (DC) cardioversion is planned.
Exclusion
- Patients with a history of known hypersensitivity or contraindication to any angiotensin II receptor blocker or any angiotensin-converting enzyme (ACE) inhibitor.
- Patients currently receiving an ACE inhibitor or angiotensin II antagonist because of heart failure or other strong indication.
- Patients currently receiving any antiarrhythmic medication including sotalol. Other beta-blockers will not be regarded as specific antiarrhythmic agents.
- Significant renal artery stenosis and any medical condition in which administration of a vasodilator is contraindicated; serum creatinine \> 225 micromol/L; or serum potassium \> 5.5 mmol/L; or serum sodium \< 128 mmol/L.
- Patients with severe hepatic dysfunction.
- Life-limiting disease or substance abuse which may affect participation.
- Patients unwilling to participate.
- Patients who have previously undergone DC cardioversion for atrial fibrillation within the last month.
- Thyrotoxicosis.
- Patients with a systolic blood pressure of \< 100 mm Hg.
- Hypertensive patients requiring intensified treatment prior to DC cardioversion.
- Pregnancy or lactation.
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00130975
Start Date
April 1 2001
End Date
September 1 2005
Last Update
January 4 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Ulleval University Hospital
Oslo, Norway, 0407
2
Asker & Baerum Hospital
Rud, Norway, 1309